GH

$156.91-$2.63 (-1.65%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$22.2B

134M shares

52-week range

$53.40 – $176.58

84% from low

Sector

SERVICES-MEDICAL LABORATORIES

Exchange

NASDAQ

Change+$57.97

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$1.3B	+38.1%	$-3.10	$-3.30–$-2.79	—	12
2027	$1.8B	+33.6%	$-1.96	$-4.29–$3.65	—	12
2028	$2.4B	+35.8%	$-0.11	$-0.33–$0.10	—	7
2029	$3.1B	+28.1%	$2.58	$2.33–$3.01	60.8×	2

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-07-30	$-0.76	$-0.90	-18.1%
2026-05-07	$-0.81	$-0.85	-5.5%
2026-02-19	$-0.77	$-0.90	-17.4%
2025-10-29	$-0.48	$-0.39	+18.7%
2025-07-30	$-0.52	$-0.44	+15.4%
2025-04-30	$-0.61	$-0.49	+19.7%
2025-02-20	$-0.75	$-0.62	+17.3%
2024-11-06	$-0.55

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GHGuardant Health, Inc.	$158.32	-0.76%	$21.2B	—
ASNDAscendis Pharma A/S	$246.46	+0.09%	$15.3B	—
BBIOBridgeBio Pharma, Inc.	$80.16	-1.30%	$15.7B	—
EHCEncompass Health Corporation	$123.33	-0.18%	$12.2B	—
EXASExact Sciences Corporation	$104.91	+0.00%

Guardant Health, Inc. Common Stock

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

www.guardanthealth.com

Employees: 2,506
IPO / List date: Oct 4, 2018
HQ: PALO ALTO, CA

Held by traders on TradeandTell

No one on the platform currently holds GH.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	337,600	$31.2M
Bridgewater Associatesas of 2026-03-31	13,351	$1.2M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded GH yet.

$GH chatter on StockTwits

Shang Tsung@ShangVXOBullish3d
$GH Yo, I might have to watch this one
View on StockTwits ↗
James McLay@Gator53263d
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIAQPGN5D-2FPABIhASGK8HRl5jA3VuaG7QJAXW42pRvNU-2B-2BxFiwu7NWOFvGg67Pbzu8ERfHBwv7erFxqJMSkdl93-2FFOUykcevmAF2ICSWZMmcjWbDz0nDlxw-2FaxgZnv6A1Xv6Nd6_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRgIG36Opi-2BfPD0wkS0BpMuUE7TTWCnxZR412Wi5CVRKxhi4ty7FjT9ixrlsMPYPLM5MNB7rEri-2BM5yfWwU7D0Husqc4vLyEn6PjC-2BGhmsPPSNg3YSbzOpdANfgB0jrD2sISEJx2j-2BhDdheMygK-2FJVwGlT28C-2Fha11iqceV44ALFLgANk3y6TO2ka76CtjHK9dfg7YjuAmJHf9ZIJRdu5c7JiLbbMwiMfi7p8y1KBIgaAGVZl5Z8Vz8FClAM1fyAyC11PzVy9brlHEMsK6QzJXw-3D-3D p
View on StockTwits ↗
James McLay@Gator5326Bullish4d
$GH ATH on deck. $200 will be a distant memory soon. 😎
View on StockTwits ↗
Nicholas@JFDIBullish4d
$GH Stage 2 continues, nearing ATH’s
View on StockTwits ↗
Minimalist Review@MarketIntel_4d
$GH Setting up for blue skies. Guardant Health is showing the kind of momentum I want to see in a long-term winner. The stock has ripped higher and is now trading around $168, right near its 52-week highs. After coming all the way back from the $50S, this is no longer a recovery story. It’s a momentum story. Revenue is still growing fast, with Q1 up 48% YoY, while 2026 revenue guidance was raised to $1.30B-$1.32B. If $GH clears the $176 area with volume, I’m watching closely.
View on StockTwits ↗
Draco@Cladkeeper6d
@MonkeyBananaGenius @SmallCappTrader I listened to the CEO of $TTWO a few days ago - very good future earnings reports and expansion of innovation. He said demand for games is through the roof. I'm waiting to free up some cash when I sell some positions to get into this. Analysts very positive for $RKLB - Cathie Wood buying a lot. I plan on picking up some of that. I was looking at diversifying into one healthcare stock and that how I can upon $GH . It is looking good. I'm looking for consistent growth. I'm being burned with $NVOX.X . Lots of pain with that one.
View on StockTwits ↗
Trade Gains@mr__binco6d
Option: $GH 170 C 8/21 Entry: 5.80 Notes: **
View on StockTwits ↗
Maverik@MaverikITAug 7
@Jblack500 @WAJeff @cynicaloptimist @BustaCapital @IsabellaDC $NTRA $GH $TWST ing 'Let's do the twist again' $WGS $PLSE
View on StockTwits ↗
James McLay@Gator5326BullishAug 6
$GH this filing:
View on StockTwits ↗
Unknown@JtloAug 6
$CAI ill sell when we are at $GH stock price. Long term hold
View on StockTwits ↗
EpicurusFan@WantedToRetireEarlyAug 6
$GH Guardant Health (GH) added nearly 10% at the market open on Friday to hit a new 52-week high after the blood-based cancer test maker reported Q2 2026 revenue well surpassing the consensus and raised its full-year outlook. After the market close on Thursday, the Palo Alto, California-based firm posted $335M in revenue for the quarter, beating estimates by $20.6M with ~44% YoY growth as its oncology portfolio outperformed. While its screening revenue reached $52.9M with nearly 66K Shield screening tests delivered, up from $14.8M and 16K tests in the prior-year period, its oncology portfolio added $29.1M with 38% YoY growth compared with 28%- 29% in the guidance. “Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year,” co-CEO Helmy Eltoukhy said. “Growth was fueled by strong oncology volume, with acceleration across every product,” he added.
View on StockTwits ↗
Top Stock Alerts@topstockalertsAug 5
$GH this one has the kind of persistence that gets noticed.
View on StockTwits ↗
Steve Shepherd@EskayesBullishAug 5
$CAI this is gonna be $GH 2.0. Same stock profile. No believers at first. Then, all the believers. Stock goes from $20 to $160. I own both.
View on StockTwits ↗
Albino@Albino_Trader123Aug 5
$GH Looking good here trying to curl back above ER close. Initial buy 130 on flag breakout. Looking for add over earnings gap around 164
View on StockTwits ↗
Genevieve Carrier@GenevieveCarrier146Aug 5
$SNA $EXE $MTZ $GH $INSM Snap-on benefits from professional tool demand, EXE remains execution-driven, MasTec benefits from infrastructure investment, Guardant Health advances liquid biopsy technology, and Insmed continues developing therapies for rare diseases.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.